Gen-Probe’s PCA3 Prostate Cancer Test Could Be Alternative To Biopsy
This article was originally published in The Gray Sheet
Executive Summary
Gen-Probe will seek approval for its PCA3 urine-based prostate cancer diagnostic as an alternative to the standard regimen of costly, invasive repeat biopsies for men who have abnormal PSA levels but test negative for cancer